Imetelstat

Last Updated: 04/28/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 163 publications

The patient voice: measuring what matters in lower-risk myelodysplastic syndromes treated with imetelstat.

The patient voice: measuring what matters in lower-risk myelodysplastic syndromes treated with imetelstat.

Journal: Haematologica

Published: February 11, 2026

Association between treatment-emergent cytopenias and clinical responses to imetelstat in lower-risk myelodysplastic syndromes.

Association between treatment-emergent cytopenias and clinical responses to imetelstat in lower-risk myelodysplastic syndromes.

Journal: Blood cancer journal

Published: February 03, 2026

Updates in low/intermediate-risk MDS.

Updates in low/intermediate-risk MDS.

Journal: Hematology. American Society of Hematology. Education Program

Published: December 05, 2025

US Food and Drug Administration Approval Summary: Imetelstat for Selected Patients With Low- to Intermediate-1 Risk Myelodysplastic Syndromes With Transfusion-Dependent Anemia.

US Food and Drug Administration Approval Summary: Imetelstat for Selected Patients With Low- to Intermediate-1 Risk Myelodysplastic Syndromes With Transfusion-Dependent Anemia.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: October 24, 2025

Outcomes with imetelstat in myelofibrosis: a systematic review and meta-analysis.

Outcomes with imetelstat in myelofibrosis: a systematic review and meta-analysis.

Journal: Leukemia & lymphoma

Published: October 15, 2025

Telomerase inhibitors - TMPyP4, BIBR 1532 and imetelstat - alter the adhesion potential of breast cancer MCF7 and MDA-MB-231 cells that leads to impaired ability to form spheroids.

Telomerase inhibitors - TMPyP4, BIBR 1532 and imetelstat - alter the adhesion potential of breast cancer MCF7 and MDA-MB-231 cells that leads to impaired ability to form spheroids.

Journal: Cell adhesion & migration

Published: October 14, 2025

Plain language summary of IMerge, a Phase 3 study of imetelstat versus placebo in people with lower-risk myelodysplastic syndromes and anemia.

Plain language summary of IMerge, a Phase 3 study of imetelstat versus placebo in people with lower-risk myelodysplastic syndromes and anemia.

Journal: Future oncology (London, England)

Published: October 13, 2025

Using imetelstat for lower-risk myelodysplastic syndromes.

Using imetelstat for lower-risk myelodysplastic syndromes.

Journal: Clinical advances in hematology & oncology : H&O

Published: October 06, 2025

Sequential treatment with ruxolitinib and imetelstat effectively depletes myelofibrosis hematopoietic stem and progenitor cells.

Sequential treatment with ruxolitinib and imetelstat effectively depletes myelofibrosis hematopoietic stem and progenitor cells.

Journal: Leukemia

Published: September 29, 2025

Effect of prior therapy on the clinical activity of imetelstat in patients with transfusion-dependent, ESA-relapsed or -refractory/-ineligible LR-MDS.

Effect of prior therapy on the clinical activity of imetelstat in patients with transfusion-dependent, ESA-relapsed or -refractory/-ineligible LR-MDS.

Journal: Blood cancer journal

Published: September 18, 2025

Myelodysplastic syndromes: Updates on Genomic Landscape, Molecular Subtypes, & Targeted Therapies.

Myelodysplastic syndromes: Updates on Genomic Landscape, Molecular Subtypes, & Targeted Therapies.

Journal: Current hematologic malignancy reports

Published: August 25, 2025

Imetelstat improves patient-reported outcomes and quality of life in lower-risk myelodysplastic syndromes: results from the phase III IMerge study.

Imetelstat improves patient-reported outcomes and quality of life in lower-risk myelodysplastic syndromes: results from the phase III IMerge study.

Journal: Haematologica

Published: August 21, 2025

Showing 1-12 of 163

Last Updated: 04/28/2026